Biotech Values

[DewDiligence]

China approves BMY 2-DAA HCV regimen for GT1b:

http://finance.yahoo.com/news/china-fda-approves-country-first-111900958.html

This 12-24-week combination of Daklinza (NS5A) + Sunvepra (a/k/a asunaprevir; PI) should sell well in China in the short run because the only alternative (other than the black market) is IFN + ribavirin. However, the window of opportunity for BMY is short since this regimen will become obsolete when Harvoni, Epclusa, and G/P are approved in China.

In the US and EU, Daklinza was approved for use in combination with GILD’s Sovaldi (mainly for GT3 patients), but this regimen was made obsolete by GILD’s Epclusa. BMY’s 2-DAA was never commercialized in the US or EU.